设为首页         

资讯内容 Content

[ESC2009]CURRENT OASIS 7研究解读:Shamir Mehta教授专访
国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

 编辑:国际循环网 时间:2009/9/1 11:56:00    加入收藏
 关键字:Shamir Mehta CURRENT OASIS 7研究 ACS 阿司匹林 


International Circulation:  Could you please talk about the choice of optimal strategy of early antiplatelet therapy in patients with ACS?

《国际循环》:您能谈谈ACS患者早期抗血小板治疗的最佳策略选择吗?

Professor Mehta:  All patients with acute coronary syndrome should be treated with 600mg of clopidogrel and should be taken to the CATH lab for coronary angiography.  If they are a PCI candidate they should continue on 150mg daily for one week, in addition to aspirin.  It could be either high-dose aspirin or low-dose aspirin.  If they do not have a PCI then the dose should be dropped down to 75mg daily for the duration.  That should be the standard that we now use for clopidogrel therapy.

S R Mehta教授:所有ACS患者都应当给予600 mg氯吡格雷治疗,都应当被送入导管室行冠状动脉造影。如果患者拟行PCI,则除阿司匹林(可以是大剂量也可以是小剂量)之外,应继续应用氯吡格雷150 mg/d 1周。如果患者不行PCI治疗则剂量应减为75 mg/d 作为维持剂量。这应该是我们目前应用氯吡格雷治疗的标准方法。

 

S R Mehta简介
 
Shamir Mehta
BSc (Toronto), MD (Toronto), MSc (McMaster), FRCPC
Associate Professor, Department of Medicine (Cardiology)
Associate Member, Dept of Clinical Epidemiology & Biostatistics
Director, Interventional Cardiology and Acute Coronary Syndrome Resea

上一页  [1]  [2]  [3]  [4]  

   评论发言          

相关视频

 
京ICP备15014970号-5   国际循环 版权所有  2008-2022 icirculation.com  All Rights Reserved